Abstract: Carbohydrate hydrolyzing a-glucosidases are commonly found in microorganisms present in the human intestine microbiome. We have previously reported crystal structures of an aglucosidase from the human gut bacterium Blaubia (Ruminococcus) obeum (Ro-aG1) and its substrate preference/specificity switch. This novel member of the GH31 family is a structural homolog of human intestinal maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) with a highly conserved active site that is predicted to be common in Ro-aG1 homologs among other species that colonize the human gut. In this report, we present structures of Ro-aG1 in complex with the antidiabetic a-glucosidase inhibitors voglibose, miglitol, and acarbose and supporting binding data. The in vitro binding of these antidiabetic drugs to Ro-aG1 suggests the potential for unintended in vivo crossreaction of the a-glucosidase inhibitors to bacterial a-glucosidases that are present in gut microorganism communities. Moreover, analysis of these drug-bound enzyme structures could benefit further antidiabetic drug development.
Introduction
Carbohydrate metabolism has regained interest recently because it is believed that the microbial communities living in the human gut greatly expand the range of complex carbohydrates available for conversion to simple sugars for energy. 1, 2 It is also a focus of biomass-biofuel conversion research. 3, 4 In bacterial genomes of the gut microbiota, the genes for carbohydrate transport and metabolism pathways are often significantly over-represented and highly diverged (http://www.jgi.doe.gov). 5, 6 This indicates the great adaptation of the enteric bacteria to a variety of carbohydrates present in diet of an omnivore such as man. Many of these dietary carbohydrates are being competed for with the host and are essential for the bacteria survival and growth. This allows bacterial species to colonize specific niches along the gastrointestinal tract and as result have impact on the physiology and pathology of the host. [7] [8] [9] It is believed that human gut microbiota express many enzymes that have the ability to bind and metabolize a wide range of bioactive compounds. Drugs taken orally reach the gastrointestinal tract and are exposed to the intestinal microbiota. It has been shown that microbiota-encoded enzymes are capable of transforming xenobiotics and can influence the pharmacokinetics of drugs taken orally and impact their bioavailability. [10] [11] [12] [13] Therefore, the intestinal microbiota may have a significant impact on drug bioavailability and effectiveness. However, understanding of these processes and how they impact microbiome and change its composition is very limited. 14 We have previously characterized the structure and function of an a-glucosidase (Ro-aG1) from the human gut bacterium Ruminococcus obeum 15 or
Blautia obeum after reclassification. 16 This novel member of the family 31 of glycoside hydrolases (GH31) 17 has active site structurally and functionally resembling that of human intestinal maltaseglucoamylase (MGAM), 18 thermophilic archaeon Sulfolobus solfataricus a-glucosidase MalA 19 and the reported human intestinal sucrase-isomaltase (SI). 20 However, the unique dimer structure of the exohydrolase Ro-aG1 seems to limit its substrates to dietary maltose or isomaltose, and it is less active with longer maltose oligosaccharides. a-glucosidase inhibitors such as acarbose (a naturally occurring pseudotetrasaccharide), voglibose (also naturally occurring in Streptomyces) and miglitol (derived from 1-deoxynojirimycin, isolated from plants) are the first-line drugs in noninsulindependent diabetes mellitus. 21, 22 The inhibitors reversibly bind to MGAM and SI, inhibiting carbohydrate hydrolysis in the upper small intestine, and consequently retard the absorption of glucose into bloodstream and reduce postprandial hyperglycemia. Acarbose is poorly absorbed in the intestine and is mostly excreted in feces, while some is degraded by amylase and by the colonic microbiota. 21, 23 The absorption of voglibose is similarly poor; its excretion is rapid with no metabolites measured. 24 Miglitol, in contrast, is fully absorbed in the gut. 25 There are very limited studies of the potential interactions of these a-glucosidase inhibitors with enzymes present in intestinal bacteria or whether such interactions could create adverse gastrointestinal symptoms. It was reported that the acarbose, was a poor inhibitor of Ro-aG1 in contrast to MGAM and SI. 15 The locations of the two active sites of a RoaG1 dimer seemingly restrict the access of longer linear substrates and inhibitors. 15 There are many sequence orthologs of B. obeum Ro-aG1 and other bacterial a-glucosidases, present and abundant in the intestinal microbial community.
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These carbohydrate-active enzymes may bind a-glucosidase inhibitors and potentially reduce their efficacy. This inhibitory effect may also have an impact on the carbohydrate metabolism of gut microorganisms and may be a cause of microbial population fluctuations. The details of unintended interactions of biomedically important drugs with microorganisms living in our gastrointestinal tract are little understood, although the impact of xenobiotics on the physiology and gene expression of active gut microbiota is significant. 12, 14 The characterization of the interaction of a-glucosidase inhibitors with gut bacterial aglucosidases is an early step toward the understanding of this complex system. In this study, we characterized binding of voglibose, miglitol and acarbose inhibitors to Ro-aG1 and determined crystal structures of their complexes with the enzyme. All of these inhibitors bind to the active site of Ro-aG1.
We also studied the interaction of these inhibitors with the Ro-aG1 W169Y mutant that switches specificity of the enzyme from isomaltose to maltose. These data have revealed potential in vivo crossinteraction of human a-glucosidase inhibitors with bacterial a-glucosidases present in human intestinal microbiota. We also believe that these drug-bound bacterial a-glucosidase structures and the inhibitive activities of these drugs provide beneficial information for development of more potent and specific antidiabetic medicines.
Results

Inhibition of Ro-aG1 by voglibose, miglitol, and acarbose
The interaction of three widely used a-glucosidase inhibitors with Ro-aG1 was measured with a maltose hydrolysis assay. Voglibose is isolated from Streptomyces hygroscopius limoneus. 27 This inhibitor comprises a validamine moiety and a 1,3-propanediol group [ Fig. 1(A) ]. The validamine moiety mimics the nonreducing end glucose of a sugar substrate and blocks the 21 sugar-binding subsite (-1 subsite) of a-glucosidase. Miglitol is a pseudomonosaccharide derived from 1-deoxynojirimycin and is one of the smallest a-glucosidase inhibiton. 28 The pseudomonosaccharide has a piperidine ring that is attached to a N-hydroxyethyl chain [ Fig. 1 Fig. 1(B,C) ]. Miglitol is a moderate inhibitor of WT Ro-aG1 (IC 50 5 32.0 lm), but its inhibitory activity is Tan et al. significantly reduced towards the W169Y mutant (IC 50 5 519.6 lm). Consistent with previous observations, 15 acarbose barely inhibits WT Ro-aG1 at the highest concentration of inhibitor used in the assay (15 mM), but it exhibits weak, although measurable, inhibition of the W169Y mutant. The Hill coefficients determined from fitting each dose-response curve are approximately one, consistent with the structural observation that these inhibitors bind at the active site of Ro-aG1.
Structures of ro-aG1 in complex with voglibose
Co-crystallization of WT Ro-aG1 in the presence of 10% (w/v) voglibose produced crystals of the same space group and similar unit cell dimensions as those of WT and D307A/isomaltose crystals (Table  II) . 15 There is one Ro-aG1 dimer per asymmetric unit, and each active site is occupied by one voglibose which can be easily recognized in the excellent electron density maps [ Fig. 2(A,B) ]. A secondary structure matching (SSM) superposition of the WT dimer and the WT/Voglibose dimer results in a root mean square deviation (RMSD) value of 0.66 Å , therefore showing no significant intermonomer or interdomain conformational changes upon voglibose binding. At the 21 sugar-binding subsite, the cyclohexane ring of voglibose adopts a chair conformation, similar to the glucopyranose ring of the nonreducing end glucose of isomaltose in the D307A/isomaltose complex [ Fig. 2(B,C) ]. The C2, C3, C4, and C6 hydroxyls of the validamine moiety of voglibose form hydrogen bonds to active site residues (D197, D420, and H478), similar to the equivalent hydroxyl groups of a glucose unit from the substrate. 15 The extra C5 hydroxyl of voglibose does not form any hydrogen bonds to the surrounding protein residues. In fact, the indole ring of W169 beneath the cyclohexane ring tilts about 98 (not shown in figures) compared to the Ro-aG1WT/miglitol structure as described later, seemingly to avoid close contact with the hydroxyl. The (C1) amino group, that bridges the 1,3-propanediol group at 11 subsite, forms a single hydrogen bond to the catalytic acid/base D420, a mimic of the interaction of the glycosidic oxygen of a substrate. The 1,3-propanediol group forms multiple hydrogen bonds to residues D73 and R404 and involves a water-mediated hydrogen bond network, therefore maintaining all major interactions of a substrate such as isomaltose at the 11 subsite with the surrounding protein residues. 15 Compared to the D307/isomaltose complex, the three water molecules W(1), W(2), and W(3) at the active site are conserved. However, the hydrogen bond network associated with W(1) in WT/Voglibose is modified due to the lack of the hemiacetal oxygen O5 of a glucopyranose ring in the cyclohexane ring. The hydrogen bond network associated with W(3) (at the 11 subsite) is partially changed, too.
As described earlier, the indole ring of W169 tilts about 9 degrees to accommodate the C5 hydroxyl of voglibose in the WT complex. A tyrosine in the position of W169 is apparently less likely to form a close contact to the hydroxyl group, making it energetically favorable for inhibitor binding. This may overwhelm other factors resulting from the replacement as discussed later, and partially explains why voglibose has about a one-third lower IC 50 value with the W169Y mutant compared to the WT enzyme. No other significant changes of either overall structure or active site were observed between the WT/voglibose and W169Y/voglibose complexes. The rmsd value of a monomer-to-monomer superposition of the two complexes is less than 0.22Å .
Structures of Ro-aG1 in complex with miglitol
Co-crystallization of WT Ro-aG1 with miglitol (10% (w/v) in crystallization buffer) produced crystals of similar forms as WT/voglibose (Table II) . In the The active site interaction pattern of an isomaltose in Ro-aG1 D307A/isomaltose complex. 15 The substrate-binding mode is for comparison to inhibitor-binding modes presented in this paper. The key residues at the active site (carbon atoms in yellow) and the substrate isomaltose (carbon atoms in cyan) are drawn in stick format. The carbon atoms on the pyranose ring of isomaltose at the 21 subsite are labeled. The three conserved water molecules involved in hydrogen bond network are drawn as small green spheres. The mutation D307A is highlighted in magenta.
structure, each active site of Ro-aG1 is occupied by one miglitol fitted well into electron density maps [ Fig. 3(A) ]. No overall conformational change upon the inhibitor binding was observed.
Miglitol is the smallest a-glucosidase inhibitor and occupies only the 21 subsite. Its piperidine ring also adopts a chair conformation like the bound substrate [ Fig. 2(C) ]. The C2, C3, C4, and C6 hydroxyls form hydrogen bonds or a hydrogen bond network at the active site similar to that observed in the D307/ isomaltose and WT/voglibose complexes mentioned earlier. The hydroxyl of the N-hydroethyl chain also forms a hydrogen bond to the NE on the indole ring of W271. The indole ring of W271 has to rotate (Chi1 rotation) about 308 to make this interaction possible [ Fig. 3(B) ].
Due to the movement of W271 and the interaction of the piperidine ring nitrogen to the catalytic nucleophile D307, the hydrogen bond network associated with the conserved water W(1) is changed. At the 11 subsite, there is no direct hydrogen bond between miglitol and the surrounding protein residues. However, the conserved water W(3) and another water W(4) bridge multiple hydrogen bonds between the hydroxyl of the N-hydroethyl chain to the residues of D73 and R404, which play important roles in substrate binding at the 11 subsite. The water W(4) is in a similar position as one of the hydroxyls of the 1,3-propanediol of voglibose [ Fig.  2(B) ].
The overall mode of miglitol binding at the active site of Ro-aG1 is similar to its binding to the N-terminal domain of human intestinal brushborder enzyme maltase-glucoamylase (NtMGAM), 29 a primary target of the drug. However, in the NtMGAM/miglitol complex, the hydroxyl of the Nhydroethyl chain is not involved in any interaction with NtMGAM. Miglitol is also an inhibitor of human lysosomal acid a-glucosidase (hGGA), which is critical for the degradation of glycogen to glucose in lysosomes. Mutations of the GGA gene cause glycogen storage disease type II (Pompe disease). A comparison of the unintended cross reaction product hGGA/miglitol complex and Ro-aG1/miglitol shows almost identical conformation in their active site and the inhibitor bound. 30 Miglitol also binds to the Ro-aG1 W169Y mutant without significant structural alteration except for some variation in a few solvent molecules associated with the substitution. Since miglitol contributes no direct hydrogen bonds at the 11 subsite, a small structural variation at the 21 subsite could potentially cause a large change to its binding affinity. It is possible that the W->Y mutation reduced the interaction between the inhibitor and the flanking residue; so much so that it accounts for more than a 16-fold increase in the IC 50 value of miglitol with and Ro-aG1/miglitol complexes are superimposed (monomer to monomer) with an rmsd value of 0.33Å . All active site residues and inhibitors are drawn in stick format. The carbon atoms of protein residues and voglibose of the Ro-aG1/voglibose complex are colored in cyan. The carbon atoms of protein residues and miglitol of the RoaG1/miglitol complex are colored in cyan and red, respectively. The hydrogen bond between W271 and the N-ethyl chain as discussed in the text is drawn in magenta dashed line. The conformations of active site key residues primarily involved in inhibitor binding are highly conserved. The cyclohexane ring of voglibose and the piperidine ring of miglitol are nearly overlapped. The conformational changes of some other key residues reflect their adjustments to accomodate different inhibitors.
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the W169Y mutant when compared with the WT enzyme.
Structures of Ro-aG1 in complex with acarbose
Acarbose is the first a-glucosidase inhibitor used for diabetes and is the most extensively studied. This antidiabetic drug also binds to many enzymes from all five kingdoms involved in glucose metabolism. Besides its targets, human intestinal MGAM and SI, it also binds to human pancreatic a-amylase 31 and glycogen branching enzyme (GBE1) (PDB ID: 5CLT). Arcabose has been found to be a low affinity inhibitor of wild type Ro-aG1 [ Fig. 2(B) ; Table I ], which is consistent with earlier observations. 15 Although the active sites of Ro-aG1 and NtMGAM are conserved, only the active site of NtMGAM is wide open; 18 therefore, we hypothesized that the difference in acarbose inhibition might be related to the lower accessibility of the inhibitor to the active site of Ro-aG1 due to its unique hidden position under a four-helix bundle [ Fig. 2(A) ]. 15 We first tried co-crystallization of WT Ro-aG1 by supplementing crystallization buffer with 10% (w/v) acarbose. Crystals were obtained and their structures were subsequently determined. However, no acarbose was found in these structures. Considering that the W169Y mutation switches the enzyme's substrate preference 15 and the human NtMGAM that binds acarbose does have a tyrosine at the equivalent position of Ro-aG1 W169, 18 we cocrystallized the W169Y mutant with acarbose and subsequently obtained a W169Y/acarbose complex structure (Table II) . In this structure, there are two parallel dimers residing in one asymmetric unit of the complex crystal. All four monomers are structurally ordered and the rmsd values of the pairwise SSM structural alignments of the four monomers range from 0.26 to 0.35 Å without gaps, suggesting all four monomers have the same structure. In the following descriptions and discussions, only one monomer (monomer A) and one dimer (the dimer from monomers A and B) will be used to describe the complex. Each of the four monomers binds one acarbose at its active site [ Fig. 4(A) ]. The electron densities are well-defined for the first two rings of the inhibitor, ring A and ring B [Figs. 1(A) and 4(B) ]. The densities gradually become weaker towards the two glycone rings, ring C and ring D. In all four monomers, the bound acarbose is virtually in the same conformation. The overall B-factor of acarbose and the corresponding conserved water molecules at each active site was higher (refined in full occupancies) than the surrounding protein atoms, indicating possible partial occupancy of the inhibitor. In fact, only in one monomer were all three conserved water molecules modeled and refined [ Fig. 4(A) ].
Ring A of acarbose binds to the 21 subsite [ Fig.  4(A) ]. The unsaturated cyclitol unit is in a half-chair conformation. The C2, C3, C4, and C6 hydroxyls form hydrogen bonds to Ro-aG1 similarly to what is observed in other Ro-aG1 complexes described above, particularly the Ro-aG1/voglibose complex [ Figs. 2(B,C) and 3(A) ]. The catalytic acid/base D420 interacts with the C2 hydroxyl and the bridging nitrogen between rings A and B. At the 11 subsite, the interaction of ring B to Ro-aG1 is primarily contributed by the two hydroxyls (C2 and C3 of ring B) to the residues D73 and R404 as well as the water W(3) mediated hydrogen bond network. At the 12 binding site, ring C does not form any hydrogen bond to Ro-aG1. The electron density for ring D is quite smeared, suggesting multiple conformations of the ring, but the last glycone ring potentially forms a hydrogen bond to K348 or K422 (data not shown).
The overall acarbose binding is very similar in Ro-aG1 W169Y/acarbose and NtMGAM/acarbose structures, particularly at the 21 and 11 subsites [ Fig. 5(A) ]. The lack of any interactions between the two glycone rings and Ro-aG1 explains their conformational flexibility, and it may attribute to their low affinities to both NtMGAM and Ro-aG1.
Additionally, the structure of a co-crystal of D307A mutant with acarbose was also determined (Table II) , in which only the ring A of a bound acarbose at 21 subsite has well-defined electron density while other three rings are disordered.
Discussion
Many host-targeted medicines are metabolized by gastrointestinal microbiota, though only a few of them have been studied for their influence on these microorganisms. 12, 13, [32] [33] [34] [35] [36] The molecular mechanisms underlying their interactions largely remain unanswered except for a few examples. 37 Antidiabetic a-glucosidase inhibitors that are not absorbed in the small intestine or not metabolized on their way to being excreted 21, 23 could encounter an enormous number of gut bacteria during excretion, especially in the colon. This creates a chance for a potentially unintended cross-interaction of the hosttargeted medicine with the a-glucosidases of gut microbiota. The potential in vivo cross-interaction is shown by the structures of bacterial Ro-aG1 in complex with three common human a-glucosidase inhibitors, voglibose, miglitol, and acarbose, presented here. Because of the high sequence and structural identity of the active sites of human a-glucosidases (MGAM and SI) and gut bacterial a-glucosidases such as Ro-aG1, gut bacterial a-glucosidases can process dietary carbohydrates (e.g., maltose and isomaltose) as well as be effectively inhibited by a-glucosidase inhibitors with comparable strengths. 38, 39 The nearly identical binding modes (of miglitol and acarbose) to Ro-aG1 and human NtMGAM suggest that most of the currently used a-glucosidase inhibitors can inhibit gut bacterial a-glucosidases (e.g., Ro-aG1) [ Fig. 2(A) ]. Though the NtMGAM/voglibose structure has not been reported, we believe the binding mode of voglibose to NtMGAM or other domains of MGAM and SI will be very similar to that observed in RoaG1/voglibose [ Fig. 2(B) ]. Though the active site is highly conserved, its location and any changes in nearby residues may affect the access and specificity of these aglucosidases to inhibitors. Comparing the W169Y/ acarbose and NtMGAM/acarbose structures, acarbose binding is nearly identical at the 21 and 11 subsites, while the conformation of the two glycone rings is different and flexible due to lack of interaction with the enzymes. The active site of NtMGAM is wide open for access of the substrate/inhibitor. The active site of Ro-aG1, in contrast, is hidden under a helix-bundle. The two active sites of a RoaG1 dimer face each other and are separated by about 37 Å , which is measured by the distance between the O4 atoms (ring A) of two bound acarboses. The length of one acarbose is about 19 Å (not fully stretched). It is clear that a long inhibitor like acarbose will not easily approach an active site of Ro-aG1, as indicated by IC50. Even a bound acarbose at one active site can create steric hindrance for another acarbose to reach and block the active site in the opposite subunit. This may be one of reasons that acarbose is not a good inhibitor of RoaG1. 15 However, small inhibitors like voglibose and miglitol will be much less influenced by such a steric limitation. The 6-membered rings of voglibose, miglitol and acarbose that contribute to inhibitor binding at the 21 subsite are different in their chemical composition. However, their largely similar conformations and the four hydroxyls (C2, C3, C4, and C6) that they commonly possess are the determinants of binding. At the 21 subsite, the conformations of RoaG1 residues including D197, D449, H478, and acid/ base D420, which are involved in forming hydrogen bonds to these hydroxyls, are quite conserved. Meanwhile, the residues including W169, W271, and nucleophile D307 are seemingly more or less adjustable in their positions in order to avoid close contact (in the case of voglibose binding) or form a new hydrogen bond (in the case of miglitol binding) upon inhibitor docking. The mutant D307A increased RoaG1 binding to acarbose in contrast to WT even though the improvement is very limited and only the ring A of the inhibitor is visible in the structure.
We demonstrated earlier that Ro-aG1 prefers isomaltose over maltose because of a potential clash of the indole ring of W169 with the O6 atom of the maltose glycone binding at the 11 subsite. 15 Replacing the tryptophan with a tyrosine relieves the congestion and switches the substrate specificity of RoaG1 to maltose. Because the W169Y mutant, unlike the WT, is able to form a complex with acarbose, the W169Y mutation apparently has increased the affinity for acarbose. The low affinity of the WT Ro-aG1 for acarbose, we believe, similarly results from a potential close contact of the W169 indole ring to, in this case, ring B's methyl group (C6) of acarbose at the 11 subsite [ Fig. 5(B) ]. A sidechain movement that the W169 may have to help accommodate ring B at the 11 subsite seems to be limited. Therefore, a W->Y mutation removes the potential congestion, leading to an increased affinity to acarbose. There are naturally occurring a-glucosidases with W->Y substitution and they are also present in intestinal microbiota. The reviving of an inhibitor's binding by a mutation as described above also suggests that the moiety of an inhibitor at the 11 subsite plays a subtle role in determining the affinity of an inhibitor. Miglitol is regarded as a pseudomonosaccharide, but it is not simply an analog of a monosaccharide. It has an N-hydroxyethyl chain that forms waterbridged hydrogen bonds to residues D73 and R404, which primarily interact with the moiety of the inhibitor at the 11 subsite [Figs. 2(B), 3(A) , and 4(A)]. Since Ro-aG1 does not form a complex with glucose even in the presence of elevated concentration of the monosaccharide in crystallization buffer, we believe that a simple glucose analog will not bind and inhibit Ro-aG1 either. The N-hydroxyethyl chain of miglitol could be critical in the binding of the inhibitor.
The study of the human gut microbiome has been expanding rapidly; however, the structural and functional characterization of the key molecules of these microorganisms is still in its infancy. Here, we have presented the structures and functions of the a-glucosidase Ro-aG1 from a species of Blaubia, a genus of the prominent Firmicutes division. The bacterial a-glucosidase, a representative of many sequence homologs, can process dietary carbohydrates and interact with human a-glucosidase drugs in vitro. The potential unintended crossinteraction in vivo may influence microbial population and community dynamics. Though its consequent physiological and/or pathological impact to the host is unknown and remain to be further explored, we believe for the purpose of? novel antidiabetic drug development, the understanding of such interaction between an a-glucosidase inhibitor and its potential receptor(s) from gut microbial community could be an important part of exploration.
Materials and Methods
Crystallization of Ro-aG1 or its mutants in the presence of inhibitors
The cloning of wild type Ro-aG1 into the pMCSG19 vector and the construction of site-direct mutant W169Y using the Polymerase Incomplete Primer Extension (PIPE) method 40 have been reported earlier. 15 The wild type and W169Y mutant were overexpressed in E. coli pRK1037 and purified using Niaffinity chromatography as described earlier. 41 The purified proteins, concentrated to 28-61 mg/mL, were crystallized in the presence of 10% (w/v) voglibose, miglitol, or acarbose under the same condition as that of the wild type (0.1M Bis-Tris pH 5.5, 25%(w/v) PEG3350) at 48C. 15 All crystals were cryoprotected directly in liquid nitrogen prior to X-ray diffraction data collection.
X-ray diffraction and structure determination
The X-ray diffraction data were obtained at the 19-ID beamline of the Structural Biology Center at the Advanced Photon Source at Argonne National Laboratory using the program SBCcollect. 42 The intensities were integrated and scaled with the HKL3000 suite 43 (Table II) . All structures were solved by molecular replacement using the program MolRep 44 with the Ro-aG1 wild type structure (PDB ID: 3N04) as a search template (Table II) . The model rebuilding of the enzyme and the model building of voglibose or miglitol or acarbose were performed using the program COOT. 45 All refinements including TLS refinement 46 were carried out with the program Phenix.Refine 47 (Table II) .
Inhibitor assays
Maltose hydrolysis in the presence of the inhibitors voglibose, miglitol and acarbose (all from SigmaAldrich, St. Louis, MO) was determined by the glucose oxidase/peroxidase method as described earlier in (15) . Reactions were carried out in duplicate by incubating 100 nM wild type (WT) enzyme or 20 nM W169Y with 30 mM maltose for 60 min at 378C (in 50 mM MES, 100 mM NaCl, pH 6.5). Inhibitor concentrations ranged from 1.54 mM to 15 mM. Reactions were quenched for 3 min at 958C, and then glucose was quantitated with the Glucose (GO) Assay Kit (Sigma-Aldrich, St. Louis MO). Contaminating maltase activity in the GO reagent was inhibited by 1 mM acarbose as described in (10 
